Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 9/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 4/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MPI | P34949 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30777425 | 1.00 | ERN1 (0.48) | ERN1ALDH1A1MEN1KMT2ATDP1 | |
| Valine SCHEMBL21359689 | 0.82 | SLC7A5 (0.38) | ERN1 | |
| SCHEMBL24133365 | 0.79 | ERN1 (0.50) | ERN1 | |
| SCHEMBL835332 | 0.79 | ERN1 (0.45) | ERN1ALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL835754 | 0.74 | MEN1 (0.48) | ERN1ALDH1A1MEN1KMT2ATDP1 | |
| SCHEMBL9358193 | 0.74 | CYP1A2 (0.41) | ERN1ALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL647462 | 0.72 | ERN1 (0.50) | ERN1ALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL21749483 | 0.71 | THRB (0.43) | ALDH1A1MEN1KMT2ATDP1HSD17B10 | |
| SCHEMBL21357938 | 0.70 | MEN1 (0.39) | ERN1ALDH1A1MEN1KMT2ATDP1 | |
| SCHEMBL30777418 | 0.70 | MEN1 (0.39) | ERN1ALDH1A1MEN1KMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112105610-B | Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation | 朱比连特普罗德尔有限责任公司 | 2024-01-26 | — | — | CN | disclosed |
| US-11529341-B2 | Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation | Jubilant Prodel LLC | 2022-12-20 | — | — | US | disclosed |
| US-11529341-B2 | Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation | Jubilant Prodel LLC | 2022-12-20 | — | — | US | disclosed |
| US-20210015810-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF PD1/PD-L1 INTERACTION/ACTIVATION | Jubilant Prodel LLC | 2021-01-21 | — | — | US | disclosed |
| US-20210015810-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF PD1/PD-L1 INTERACTION/ACTIVATION | Jubilant Prodel LLC | 2021-01-21 | — | — | US | disclosed |
| CN-112105610-A | Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation | 朱比连特普罗德尔有限责任公司 | 2020-12-18 | — | — | CN | disclosed |
| WO-2019175897-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF PD1/PD-L1 INTERACTION/ACTIVATION | JUBILANT BIOSYS LIMITED (IN) | 2019-09-19 | — | — | WO | disclosed |
| US-8378118-B2 | Pyrazole-based thyroid receptor compounds | TORRENT PHARMACEUTICALS LTD. (IN) | 2013-02-19 | — | — | US | disclosed |
| US-20120202816-A1 | NOVEL COMPOUNDS | TORRENT PHARMACEUTICALS, LTD. (IN) | 2012-08-09 | — | — | US | disclosed |
| US-8143424-B2 | Thyroid like compounds | TORRENT PHARMACEUTICALS LTD. (IN) | 2012-03-27 | — | — | US | disclosed |
| EP-2061766-B1 | NOVEL COMPOUNDS | TORRENT PHARMACEUTICALS LTD (IN) | 2010-08-18 | — | — | EP | disclosed |
| CN-101772487-A | Novel compound | TORRENT PHARMACEUTICALS LTD | 2010-07-07 | — | — | CN | disclosed |
| US-20100168110-A1 | Novel Compounds | TORRENT PHARMACEUTICALS LTD. (IN) | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202816-A1 | NOVEL COMPOUNDS | TSHR, THRB, GPR119 | ERN1 3029/4885ALDH1A1 1664/4885MEN1 541/4885 |
| US-20210015810-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF PD1/PD-L1 INTERACTION/ACTIVATION | CD274, PDCD1, PDCD1LG2 | ERN1 2506/4885ALDH1A1 86/4885MEN1 1016/4885 |
| US-20100168110-A1 | Novel Compounds | TSHR, THRB, GPR119 | ERN1 3029/4885ALDH1A1 1664/4885MEN1 541/4885 |
| US-11529341-B2 | Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation | CD274, PDCD1, PDCD1LG2 | ERN1 2506/4885ALDH1A1 86/4885MEN1 1016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.